Theravance Biopharma (TBPH) Misses Q4 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Needham & Company Reiterates Buy on Theravance Biopharma (TBPH) Following Conference Call
February 28, 2017 7:07 AM ESTNeedham & Company reiterated a Buy rating and $40.00 price target on Theravance Biopharma (NASDAQ: TBPH) following the company's 4Q conference call.
Analyst Alan Carr commented, "Theravance mgmt hosted a 4Q16 conference call late yesterday to provide a corporate update. We note several expected... More
